This is a preview of subscription content, log in via an institution to check access.
Change history
13 January 2016
In Table 1, the highest threshold for PD-L1 positivity with the Ventana SP142 diagnostic for immune cells was given as 50%; the threshold is 10%. In addition, in Box 1, the name of company Arcteris was misspelled as Arcteries. The errors have been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Predictive biomarkers for checkpoints, first tests approved. Nat Biotechnol 33, 1217–1218 (2015). https://doi.org/10.1038/nbt1215-1217
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1215-1217
- Springer Nature America, Inc.
This article is cited by
-
Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment
Cancer Immunology, Immunotherapy (2019)
-
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Pathology (2018)
-
Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy
Nature Biotechnology (2017)
-
Genentech's PD-L1 agent approved for bladder cancer
Nature Biotechnology (2016)
-
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
International Journal of Clinical Oncology (2016)